Exhibit 10.33
KIRBY EMPLOYMENT AND NON-COMPETE AGREEMENT
The parties to this Employment Agreement (this "Agreement") are PHC, Inc.,
a Massachusetts corporation ("PHC,") and its subsidiary, Pivotal Research
Centers, LLC, an Arizona limited liability company ("Pivotal," and, together
with PHC, the "Company"), and Louis C. Kirby (the "Executive").
RECITALS:
A. PHC is a Massachusetts corporation engaged in the business of providing
behavioral health services and Clinical Research Services.
B. PHC currently conducts Clinical Research Services through operating
divisions and subsidiaries (including but not limited to Pioneer
Pharmaceutical Research, Inc. ("PPR"), a wholly owned subsidiary of PHC) at
facilities located in Michigan, Nevada and Utah.
C. Pivotal is a nationally recognized provider of Clinical Research Services
to Pharmaceutical Companies, with clinical research facilities located in
Peoria, Arizona and Mesa, Arizona.
D. Executive has served as the CEO of Pivotal prior to its acquisition by PHC
on the date of this Agreement.
E. Company desires to have Executive serve as the Chief Medical Director of
all of the Company's clinical research operations and activities (including
but not limited to the activities conducted by PHC, Pivotal and PPR), with
Executive reporting directly to the CEO of the Business (defined below),
and Executive desires to provide such services to the Company, subject to
the terms and conditions set forth below.
AGREEMENT
Now, therefore, with reference to the foregoing recitals, all of which are
incorporated herein by this reference, and for other good and valuable
consideration, the receipt and adequacy of which are hereby acknowledged, the
parties hereto agree as follows:
1. Employment, Term and Duties.
1.1 Employment. Pivotal hereby agrees to employ Executive as the
Chief Medical Director of Pivotal for the Term set forth in
Section 1.2. PHC hereby agrees to employ Executive as the Chief
Medical Officer of PHC divisions, subsidiaries or affiliates
engaged in the Clinical Research Services business for the Term
set forth in Section 1.2. Executive shall perform all duties
incident to such offices and such other duties as are reasonably
assigned to Executive by the CEO of the Business, the Board of
Directors of Pivotal, or the Board of Directors of PHC. For
purposes hereof, the "Business" means the business of providing
Clinical Research Services to Pharmaceutical Companies. The
parties understand and acknowledge that PHC's current corporate
-- 123 --
structure as it relates to Clinical Research Services, including
the structure that will exist immediately Post-Closing, may need
to be modified over time to improve the operational efficiency of
the Business, and all parties understand and agree that such
restructuring shall in all cases be consistent with Executive's
role as the Chief Medical Director of the Business.
1.2 Term. The term of Executive's employment under this Agreement
shall commence on the date of this Agreement and shall continue
through December 31, 2006, unless sooner terminated pursuant to
Section 4 (the "Initial Term"). Thereafter, this Agreement shall
automatically and without further action be renewed for
successive one-year periods (each a "Renewal Term") on the same
terms and conditions unless sooner terminated pursuant to Section
4 hereof or by either party not less than 60 days prior to the
expiration of the Initial Term or any Renewal Term. As used
herein, "Term" shall mean the Initial Term and any Renewal Term.
1.3 Duties. During the Term, Executive shall report directly to the
CEO of the Business and perform the duties set forth in attached
Exhibit A and such reasonable additional duties related to the
Business as may be assigned from time to time by the CEO of the
Business.
1.4 Best Efforts. Executive shall devote his best efforts in
promoting the Company's interests, and performing his duties and
responsibilities. Executive shall devote his full working time to
the Business and the Company. Executive's services under this
Agreement shall be performed primarily at the Locations or at
such other primary office as determined mutually by the CEO of
the Business and Executive, subject to reasonable travel
requirements on behalf of the Business or the Company. The
Company hereby acknowledges and agrees that the Company has no
right to review, restrict or take any ownership interest in or
receive any revenues from any activities undertaken by Executive
during non-business hours, provided such activities shall not:
(i) involve the performance or provision of Clinical Research
Services; (ii) interfere with Executive's performance of his
duties under this Agreement; or (iii) violate applicable law.
1.5 Defined Terms. Any capitalized terms not defined herein shall
have the meaning set forth in that certain Membership Interest
Purchase Agreement (the "Purchase Agreement") between PHC,
Pivotal, Executive, Carol Colombo and Anthony Bonacci of even
date herewith.
2. Compensation.
2.1 Base Salary. During the Term, as compensation for the services
rendered by Executive to the Company, PHC and Pivotal shall pay
to Executive a single base salary at an annual rate of not less
than $200,000 (the "Base Salary"). The Base Salary shall be
payable in accordance with Pivotal's regular payroll practices
(but no less frequently than monthly) less federal and state
-- 124 --
income tax withholding, other deductions required by law and
other normal deductions. The Base Salary shall be subject to
adjustment from time to time (but to no less than $200,000) by
the Board of Directors in its discretion. The Board of Directors
shall review Executive's Base Salary no less frequently than
annually to determine whether or not to make any adjustment in
light of the duties, responsibilities and performance of
Executive and the performance of the Company.
2.2 Incentive Compensation. During the Term, Executive shall be
entitled to receive incentive compensation (a "Bonus") based on
the Adjusted EBITDA (as defined in Note A): If Adjusted EBITDA of
the Pivotal Business is:
Equal to or greater than $780,000, Then Pivotal pays to
Executive $30,000 Bonus
less federal and state
income tax withholding,
other deductions required
by law and other normal
deductions
2.3 Employee Benefits. During the Term, Executive, subject to
eligibility and other terms shall be entitled to participate in
any employee benefits plans and programs from time to time
established by the Company including, without limitation, any
group health plans, insurance plans, life insurance plans, profit
sharing, vacation, pension and other benefit plans adopted by the
Company. Executive shall be entitled to four weeks paid vacation.
2.4 Expense Reimbursement. The Company shall promptly pay all
reasonable expenses which are actually incurred by Executive on
behalf of the Company incident to the discharge and performance
of Executive's duties hereunder including, but not limited to,
business expenses for travel, as evidenced by vouchers and such
other reasonable supporting materials as the Company may require.
Executive shall properly account for all expenses and shall
maintain such records with respect thereto as are in accordance
with the policies and practices determined by the Board in effect
from time to time.
2.5 Auto Allowance. During the Term, Executive shall be entitled to
an automobile allowance of twenty-six payments of Four Hundred
Fifty Dollars ($450.00) during any given calendar year of the
Term in accordance with Pivotal's customary payroll practices.
Such auto allowance shall be in addition to other compensation
paid to Executive.
3. Covenants of Executive. In order to induce the Company to enter into
this Agreement, Executive hereby covenants as follows:
-- 125 --
3.1 Inventions and Innovations. Executive agrees that all right,
title and interest in and to any innovation, design, technique,
process, idea, product, system, program, machine, method or
improvement which are or have been developed or created in whole
or in part by Executive at any time and at any place during the
term of his employment by the Company and related to or usable in
connection with the business activities of the Company shall be
and remain forever the sole and exclusive property of the Company
unless otherwise agreed to in writing between the parties.
Executive further agrees to promptly reveal all information
relating to the same to the Board and to cooperate with the
Company and execute such documents as may be necessary in the
event that the Board desires to seek protection on behalf of the
Company thereafter.
3.2 Covenant Not To Compete. In consideration of the consummation of
the transactions contemplated under this Agreement, Executive
hereby covenants and agrees that for the period beginning on the
date hereof and ending upon the later to occur of (i) five (5)
years from the Closing Date (as defined in the Purchase
Agreement), or (ii) two (2) years after the Date of Termination,
Executive will not, alone or in association with others, either
as a principal, agent, direct or indirect owner, shareholder,
partner, joint venturer or member, officer, director, employee,
lender, investor, consultant, manager, or in any other capacity:
(a) Recruit or hire any employee of the Company, or otherwise
attempt to solicit or induce any employee of the Company to
leave the employment of the Company.
(b) Solicit any customer or Prospective Customer of the Company
or otherwise interfere with the business relationships
between the Company, its customers or Prospective Customers,
suppliers and others with whom the Company conducts its
Clinical Research Services business.
(c) Perform any service for any customer or Prospective Customer
of the Company which is competitive in any manner with
Clinical Research Services which the Company may perform for
such customers or Prospective Customers, regardless of
whether the Company has or is now providing such Clinical
Research Services.
(d) Executive shall not directly or indirectly solicit for
employment on Executive's own behalf, or on behalf of any
other enterprise, any individual who is or has been an
employee, agent or independent contractor of the Company in
a capacity related or pertaining to Clinical Research
Services.
-- 126 --
This covenant not to compete shall in no way restrict the rights of
Executive to hold 5% or less of the equity securities of any corporation whose
equity securities are listed on a national securities exchange or are regularly
traded in the over-the-counter market and for which quotations are available on
the National Association of Securities Dealers Automated Quotation System.
3.3 Confidentiality. Executive acknowledges that, by virtue of
his involvement with the Company, he has been, and in the
future will be, exposed to and has had access, and, in the
future will have access, to trade secrets, processes,
computer programs, financial data and information, marketing
information, customer information, pricing information,
customer lists, information relating to the business or
operations of the Company and any other information,
software, equipment or processes which are used in
connection with or relate to the Company or its members,
managers, employees, customers or other vendors or which are
otherwise proprietary to or in the possession of the Company
("Confidential Information") except where such Confidential
Information (i) was or becomes generally available to the
public other than as a result of a disclosure by Company or
its affiliates to one or more unauthorized parties, (ii) is
required by law to be disclosed or (iii) is made generally
available to the public by the Company. Executive further
acknowledges that his expertise, knowledge and experience
in, of and with the Company would enable him to use such
information to benefit individuals or entities other than
the Company. Executive hereby covenants and agrees as
follows:
(a) During the Term and at all times thereafter, the
Confidential Information shall be kept confidential by
Executive, will not be used in any manner which is
detrimental to the Company or its shareholders,
members, managers or employees, and will be safeguarded
by Executive from unauthorized disclosure. Executive
also agrees that Executive will disclose to the Person
or Persons designated by the Company all Confidential
Information.
(b) Following the expiration of the Term, Executive will
return to the Company any Confidential Information
currently in his possession or control or which may
subsequently come into his possession or control, will
not retain any copies, including non-conforming copies,
thereof, including, without limitation, all analyses,
compilations, studies or other documents in whatever
form, including magnetic media, prepared by Executive
or for Executive's use containing or reflecting any
Confidential Information. Executive shall not disclose
to the Company, use in the Company's business, or cause
the Company to use, any confidential or proprietary
information or materials of any third party.
-- 127 --
3.4 Enforcement by Injunction. Executive acknowledges that the
protections of the Company set forth in Sections 3.1, 3.2 and 3.3
of this Agreement are of vital concern to the Company, that
monetary damages for any violation thereof would not adequately
compensate the Company and that the Company is engaged in a
highly competitive business. Accordingly, Executive agrees that
the restrictions set forth in Sections 3.1, 3.2 and 3.3 are
reasonable and that, in addition to any other remedy, the Company
shall be entitled to enforce such Sections by injunction whether
or not Executive's employment hereunder has terminated. Executive
hereby waives any requirement of a bond for such enforcement by
injunction.
3.5 Early Termination of Restrictive Provisions. The restrictive
covenant set forth in Section 3.2 of this Agreement shall
terminate immediately upon the occurrence of (i) any termination
of Executive not for Cause, (ii) any termination of Michael J.
Colombo under the Colombo Employment Agreement not for Cause, or
(iii) an "Event of Default" under any Note which is due to PHC's
failure or refusal to pay amounts due to Sellers thereunder which
such failure or failures continue for an aggregate period of not
less than six (6) months during the Terms of any such Notes.
3.6 Partial Enforcement. If any term or condition of this Agreement
shall be invalid or unenforceable to any extent or in any
application, then such term or condition shall automatically, and
without any further action, be reformed so as to retain the
fullest extent of any restriction therein permitted by law and
the remainder of this Agreement, and such term or condition,
except to such extent or in such application, shall not be
affected thereby, and each and every term and condition of this
Agreement shall be valid and enforced to the fullest extent and
in the broadest application permitted by law.
3.7 Cumulative Rights. Each and all of the various rights, powers and
remedies of the Company as set forth in this Agreement shall be
considered as cumulative, with and in addition to any other
rights, powers or remedies of such parties, and no one of them is
exclusive of the others or is exclusive of any other rights,
powers and remedies allowed by law or in equity. The exercise,
partial exercise or non-exercise of any rights, powers or
remedies shall constitute neither the election thereof nor the
waiver of any other rights, powers or remedies. All rights,
powers and remedies of the parties hereto shall survive the
termination of this Agreement.
3.8 Merger or Reorganization. The Company may assign its rights under
this Agreement in accordance with Section 10.10 of the Purchase
Agreement.
3.9 Enforcement. Executive agrees and warrants that the covenants
contained herein are reasonable, that valid consideration has
been and will be received therefore and that the agreements set
forth herein are the result of arms-length negotiations between
the parties hereto. Executive recognizes that the provisions of
this Article 3 are important to the continuing welfare of the
-- 128 --
Company, and that money damages are an inadequate remedy for any
violation thereof. Accordingly, in the event of any such
violation by Executive, Pivotal or PHC, in addition to any other
remedies they may have, shall have the right to institute and
maintain a proceeding to compel specific performance thereof or
to issue an injunction restraining any action by Executive in
violation of this Article 3.
4. Termination of Employment.
4.1 Death or Disability. Executive's employment under this
Agreement shall terminate upon his death or Disability.
Executive shall be deemed to be Disabled in the good faith
determination of the Board. At any time and from time to
time, upon reasonable request therefore by the Company,
Executive shall submit to reasonable medical examination for
the purpose of determining the existence, nature and extent
of any such disability. The Company shall promptly give
Executive notice of any such determination of Executive's
Disability and of the decision of the Company to terminate
Executive's employment by reason thereof. In the event of
Disability, until the Date of Termination the Base Salary
payable to Executive under Section 2.1 shall be reduced
dollar-for-dollar by the amount of disability benefits, if
any, paid to Executive in accordance with any disability
policy or program of the Company. "Disability" shall mean
the inability of Executive, by reason of any medically
determinable physical or mental impairment for a period of
90 days during any 12 month period, regardless of the
Executive's presence or absence at his place of employment,
to carry out and perform the duties and obligations
ordinarily required of Executive.
4.2 Termination by the Company.
(a) With or Without Cause. The Company may terminate
Executive's employment under this Agreement with or
without Cause. "Cause" means, (i) commission of any
dishonest act by Executive in connection with
Executive's performance of activities including,
without limitation, but not limited to, an act of
fraud, embezzlement or willful breach of a fiduciary
duty to the Company, (ii) drunkenness or intoxication
while engaged in Company business or the use of drugs
or alcohol in a manner which adversely affects
performance of the Executive's activities, (iii)
diversion of any corporate opportunity of the Company
for Executive's direct or indirect benefit, (iv)
commission by Executive of any act of sexual
harassment, discrimination or other violation of any
similar statute, ordinance, law or regulation regarding
human rights, (v) any act or omission by Executive
which causes the disqualification, expiration or
termination of the Company's license which is issued by
any governmental or quasi governmental authority under
any statute governing the business or operations of the
Company and which such disqualification, expiration or
-- 129 --
termination has a Material Adverse Effect upon the
Company's ability to conduct business, (vi) the breach
by Executive of Article 3 of this Agreement, or (vii)
Executive's failure to use commercially reasonable
efforts to perform his duties under this Agreement and
Executive's failure to cure such non-performance within
thirty (30) calendar Days after receipt of written
notice from the Company specifying the nature of such
failure, or if such failure is not capable of being
cured within thirty (30) calendar days, Company's
acceptance, in writing, of a written plan of action
submitted to the Company, in writing, within ten (10)
calendar days of receipt of such notice from the
Company, that sets forth a reasonable plan for
Executive's cure of the failure, provided, however,
that two or more occurrences of Executive's failure to
use commercially reasonable efforts to perform his
duties under this Agreement during the term of this
Agreement shall, at Company's option, constitute an
immediate termination for Cause.
4.3 Termination by Executive. Upon thirty days prior
written notice Executive may terminate his employment
under this Agreement with or without Good Reason (as
defined below) If such termination is with Good Reason,
Executive shall give the Board of PHC written notice,
which shall identify with reasonable specificity the
grounds for Executive's resignation. For purposes of
this Agreement, "Good Reason" shall mean any of the
following: (i) a reduction in Executive's compensation
in violation of Section 2.1 of this Agreement, which
reduction is accomplished without the prior written
consent of Executive, (ii) a material diminution in
Executive's duties and responsibilities under this
Agreement for a period of one month or more other than
by virtue of Executive's Disability, which material
diminution is accomplished without the prior written
consent of Executive, or the mutual written agreement
of Executive and Company, or the unilateral conduct of
the Executive, (iii) the failure to pay any of
Executive's compensation when due (including any
Bonus), except in the case of Executive's breach of
this Agreement or any other agreement between
Executive, the Company or its affiliates, (iv) any
material breach of, or material failure of the Company
to perform, any material provision of this Agreement,
including but not limited to, the Bonus provisions
contained in Sections 2.2, and the failure of such
breaching party to cure such breach or non-performance
within the applicable "Cure Period", or (v) any failure
by PHC to fund the Company's working capital
requirements in accordance with the terms and
conditions and in the amount set forth in Section 3.5
of the Purchase Agreement, which failure would
materially impair Executive's ability to perform the
-- 130 --
duties set forth in attached Exhibit A. For purposes of
this Agreement, the term "Cure Period" shall mean a
period of time that commences upon the giving of
written notice by a non- defaulting party to the
defaulting party(ies) that a breach or failure to
perform has occurred and expires ten (10) calendar days
from the date such notice is given or deemed given.
Executive may terminate his employment under this
Agreement with or without Good Reason (as defined
above). If such termination is with Good Reason,
Executive shall give the Company written notice, which
shall identify with reasonable specificity the grounds
for Executive's resignation.
4.4 Date of Termination. "Date of Termination" shall mean
the earlier of (a) the expiration of the Term, and (b)
if Executive's employment is otherwise terminated
whether by Executive or by Pivotal or PHC, the date on
which Executive's employment with the Company actually
terminates.
4.5 No Event of Default under Transaction Documents. Any
termination of this Agreement by Pivotal, PHC or
Executive (whether with or without Cause and whether
with or without Good Reason) shall not independently
constitute an event of default for purposes of the
Transaction Documents, and no independent action
initiated by Executive, PHC or Pivotal for a breach of
the terms and conditions of this Agreement shall give
rise to a separate cause of action under the
Transaction Documents except the rights specifically
set forth in the Notes.
5. Compensation Upon Termination.
5.1 As a Result of Death, Disability, Cause or Resignation.
(a) Death or Disability. Subject to Executive's continuing
compliance with the terms of this Agreement, if Executive's
employment under this Agreement is terminated prior to the
expiration of the Term by reason of his death or disability,
then Executive (or in the case of his death, his personal
representative) shall be entitled to receive the the amount
of his Accrued Obligations (as defined below), such amount
to be paid in accordance with the Company's ordinary and
customary payroll practices. As used in this paragraph,
"Accrued Obligations" means, as of the Date of Termination,
(i) any payments which Executive may be entitled to receive
pursuant to any Company employee benefits plan or program,
(ii) any earned but unpaid Base Salary as of the date of
such termination, or (iii) any accrued and unpaid expense
reimbursements or auto allowance pursuant to Sections 2.4
and/or 2.5, (iv) any accrued or earned and unpaid Bonus
pro-rated through the Date of Termination.
-- 131 --
(b) Termination for Cause; Resignation Without Good Reason. If
Executive's employment under this Agreement is terminated
prior to the expiration of the Term by reason of his
termination by the Company for Cause or his resignation
without Good Reason, then Executive shall solely be entitled
to receive the following benefits: (i) any benefits which
Executive may be entitled to receive pursuant to any Company
employee benefits plan, (ii) any earned, but unpaid Base
Salary, and (iii) any accrued but unpaid expense
reimbursements, subject to Section 2.4, or auto allowance
pursuant to Section 2.5.
5.2 By Executive for Good Reason or the Company other than for Cause.
If, prior to scheduled expiration of the Term, the Company terminates
Executive's employment without Cause, or Executive terminates his employment for
Good Reason, Executive shall be entitled to receive the Accrued Obligations
described in Section 5.1(a).
5.3 No Mitigation. Executive shall not be required to mitigate the
amount of any payment or benefit provided for in this Section 5
by seeking other employment or otherwise, and, except as
otherwise expressly provided in Sections 5.1 or 5.2, the amounts
of compensation or benefits payable or otherwise due to Executive
under this Section 5 or other provisions of this Agreement shall
not be reduced by compensation or benefits received by Executive
from any other employment he shall choose to undertake following
termination of his employment under this Agreement.
6. Miscellaneous.
6.1 Binding Effect. This Agreement shall be binding upon and inure to
the benefit of the heirs and representatives of Executive and the
successors and assigns of the Company.
6.2 Notices. All notices or other communications hereunder shall be
made in writing and shall be deemed duly given (a) when
personally delivered to the intended recipient (or an officer of
authorized representative of the intended recipient), (b) on the
day of transmittal when sent by facsimile with confirmation of
receipt if sent prior to 5:00 pm, or on the immediately following
day if sent after 5:00 pm, (c) on the first business day after
the date sent when sent by a nationally recognized overnight
courier service, or (d) three business days after it is sent by
first class U.S. mail, postage prepaid, to the intended recipient
at the address set forth below:
-- 132 --
(a) to PHC or Pivotal, to it at:
PHC, Inc.
200 Lake Street, Suite 102
Peabody, MA 01960
Attention: Bruce A. Shear, President
Facsimile No.: (978) 536-2677
with a copy to:
Arent Fox Kintner Plotkin & Kahn, PLLC
1050 Connecticut Avenue, NW
Washington, DC 20036-5339
Attention: J. Aaron Ball, Esq.
Facsimile No.: (202) 857-6395
(b) to Executive, at the address set forth in the Purchase
Agreement.
Any party may change the address to which notices and communications hereunder
are to be delivered by giving the other parties notice in the manner set forth
herein.
6.3 Construction. As used in this Agreement, unless the context otherwise
requires: (i) references to "Section" are to a section of this
Agreement; (ii) all "Exhibits" referred to in this Agreement are to
Exhibits attached to this Agreement and are incorporated into this
Agreement by reference and made a part of this Agreement; (iii)
"include", "includes" and "including" are deemed to be followed by
"without limitation" whether or not they are in fact followed by such
words or words of like import; (iv) the headings of the various
sections and other subdivisions of this Agreement are for convenience
of reference only and shall not modify, define or limit any of the
terms or provisions of this Agreement; and (v) "knowledge" of a person
means the actual knowledge of such person and the knowledge that a
prudent individual could be expected to discover or otherwise become
aware of in the course of conducting a reasonable investigation
concerning the existence of the matters addressed.
6.4 Assignment. This Agreement shall not be assignable by Executive.
6.5 Execution in Counterparts. This Agreement may be executed in two or
more counterparts, and by facsimile signature, each of which shall
constitute an original, but all of which together shall constitute but
a single instrument.
6.6 Jurisdiction and Governing Law. This Agreement shall be governed by
and construed in accordance with the laws of the State of Arizona
applicable to agreements made and to be performed in Arizona. Any and
all disputes arising out of, related or pertaining to this Agreement
shall be resolved in accordance with the Arbitration provisions set
forth in Section 10.12 of the Purchase Agreement.
6.7 Severability. If any provision of this Agreement, or the application
of any provision to any person or circumstance, shall for any reason
and to any extent be invalid or unenforceable, the remainder of this
Agreement and the application of that provision to other persons or
circumstances shall not be affected but shall be enforced to the full
extent permitted by law.
-- 133 --
6.9 Complete Agreement; Modification and Termination. This Agreement
contains a complete statement of all the arrangements among the
parties with respect to its subject matter, supersedes all existing
agreements among them concerning that subject matter and may be
modified, waived or terminated only by a written instrument signed by
the parties.
IN WITNESS WHEREOF, the parties hereto have executed and delivered this
Agreement as of the day and year first above written.
PHC, Inc.
By: /a/ Bruce A. Shear
______________________
Name: Bruce A. Shear
Title: President
Pivotal Research Centers, L.L.C.
By: /a/ Bruce A. Shear
______________________
Name: Bruce A. Shear
Title: President
EXECUTIVE
/s/ Louis C. Kirby
______________________
Louis C. Kirby
-- 134 --
Exhibit A
Executive Job Description
1. Oversee Business Development Activities for Pivotal, including soliciting
studies in core indication areas, identifying and providing recommendations
for new indications, promoting Pivotal as a research center, sharing
Pivotal study leads for distribution to other Clinical Research Services
sites within the PHC system; and nurturing and building industry
relationships.
2. Participate in direct patient care as an Investigator. Advise on clinical
operations at all Clinical Research Services sites, and provide or assist
with additional clinical staff training, as necessary.
3. Assist with Clinical Research Services within the PHC system, including
evaluating study capabilities of existing investigators; identifying
physician candidates at each site; mentoring physicians in business
development; identifying key industry meeting and speaking engagements in
which Pivotal investigators are introduced to sponsors and key industry
people.
4. Participate and provide input to corporate strategic planning activities.
-- 135 --